EUROFINS VIRACOR, INC. – Trademark Portfolio
Entity Type: 03
EUROFINS VIRACOR, INC. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include IMMUKNOW and T CELL FX. The owner is based in LEE'S SUMMIT, NJ.
1001 N. W. TECHNOLOGY DRIVE
LEE'S SUMMIT, NJ 64086
Showing of trademarks Trademarks
Trademark Classifications
EUROFINS VIRACOR, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Frequently Asked Questions
How many trademarks does EUROFINS VIRACOR, INC. have?
EUROFINS VIRACOR, INC. has 5 U.S. trademarks filed with the USPTO. Of these, 3 registered, 2 cancelled.
What trademark classes does EUROFINS VIRACOR, INC. file in?
EUROFINS VIRACOR, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 44 (Medical Services), Class 16 (Paper Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are EUROFINS VIRACOR, INC.'s most well-known trademarks?
EUROFINS VIRACOR, INC.'s registered trademark portfolio includes well-known marks such as IMMUKNOW and T CELL FX. These are among 3 currently registered trademarks in the portfolio.
What is EUROFINS VIRACOR, INC.'s trademark registration success rate?
EUROFINS VIRACOR, INC. has a 60% trademark registration rate, with 3 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.